Pathos

Biotech & Life Sciences · Chicago, United States · Founded 2022

Reimagining drug discovery and development through the lens of technology, with an AI intelligence platform MoreLess

Pathos is a biotechnology company that operates at the intersection of artificial intelligence and oncology. The company's core mission is to accelerate the development of cancer drugs by leveraging a sophisticated platform that integrates vast amounts of oncology data, including genomic information.

Pathos utilizes advanced AI and machine learning algorithms to analyze this complex data, aiming to re-engineer the drug development process. This data-driven approach allows the company to identify and validate novel therapeutic targets and biomarkers, ultimately leading to more effective and personalized cancer treatments.

The company's business model is centered on collaborating with pharmaceutical and biotechnology partners to advance their oncology pipelines. By providing its AI-powered platform and insights, Pathos helps its clients to de-risk drug development, reduce timelines, and increase the probability of success for new cancer therapies. The company serves a clientele of researchers, drug developers, and clinicians in the oncology space.

Keywords: biotechnology, artificial intelligence, oncology, drug development, genomics, machine learning, cancer treatment, personalized medicine, therapeutic targets, biomarkers

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Knowledge graph

News Pathos AI acquires majority stake in DeuterOncology for AI-sourced cancer drug Jun 3, 2026

Talent graph

Pathos's talent

Book a demo to see the people

Employees mapped 98 incl. 4 AI specialists

Founders /100 quality score

Key operators 9 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Pathos's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage

NEA

Lightbank

Revolution

Builders VC

Global footprint

Where Pathos has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

7.4K monthly visits
across markets

🇺🇸 United States82.4%

🇮🇳 India16.2%

🇯🇵 Japan0%

Top 3 markets shown

Patent intelligence

$39k patent portfolio · 1 active families

Estimated portfolio value

$39k

<0.01% of valuation · 12513.2× smaller than top peer Genmab ($488M)

1 active patent families

Where Pathos innovates Animal bodyCancer preventionCancer researchCarcinosisCultured Cell Line

Where Pathos concentrates vs peers

Each axis is a top-10 topic across Pathos and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Pathos

An AI-synthesized read of the highest-engagement posts about Pathos on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pathos on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles